Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04144348 · ClinicalTrials.gov registry record · Phase 1
Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure
A Phase 1 study of Human Metapneumovirus and Human Parainfluenza Infection, sponsored by ModernaTX.
- Completed
- Registry status
- Phase 1
- Development phase
- 51
- Enrollment target
- 19
- Study locations
NCT04144348: Completed Phase 1 study of Human Metapneumovirus and Human Parainfluenza Infection, sponsored by ModernaTX.
NCT04144348 is a Phase 1 study of Human Metapneumovirus and Human Parainfluenza Infection that has completed, run by ModernaTX. The registered enrollment target is 51 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (15% lower). The trial reports 19 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04144348, a Phase 1 study of Human Metapneumovirus and Human Parainfluenza Infection, has completed, sponsored by ModernaTX.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 51 participants
- Enrollment target
- 19
- Study locations
Study Summary
This clinical study will assess the safety and immunogenicity of 2 dose levels of mRNA-1653, a combined human metapneumovirus and human parainfluenza virus type 3 vaccine, in healthy adults (18 to 49 years of age) and 2 dose levels in children (12 to 59 months of age) with serologic evidence of prior exposure. The safety profile of the adult cohort will permit enrollment of the pediatric cohort.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL mRNA-1653
Study Locations (19)
Nebraska
- Meridian Clinical Research, LLC - Lincoln
- Meridian Clinical Research - Norfolk
- Meridian Clinical Research, LLC - Omaha
New York
- UHS Primary Care - Binghamton
- Child Healthcare Associates - Liverpool
- Child Healthcare Assoc. - Syracuse
Texas
- Crossroads Clinical Research - Corpus Christi
- University of Texas Medical Branch (UTMB) - Galveston
- Tekton Research Inc - San Antonio
Kansas
- Heartland Research Associates LLC - El Dorado
- Heartland Research Associates LLC - Newton
Alabama
- Central Research Associates Inc - Birmingham
District of Columbia
- Meridian Clinical Research - Washington D.C.
Idaho
- Clinical Research Prime - Idaho Falls
Louisiana
- MedPharmics - Metairie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2019-11-04 |
| Est. Completion | 2022-12-20 |
| Phase | Phase 1 |
What the finished NCT04144348 record still lists
NCT04144348 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (15% lower).
The record links to 1 condition, with Human Metapneumovirus and Human Parainfluenza Infection appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04144348 lists 19 locations in 12 states (Nebraska, New York, Texas).
Frequently Asked Questions
What is clinical trial NCT04144348 about?
NCT04144348 is a clinical study titled "Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure". This clinical study will assess the safety and immunogenicity of 2 dose levels of mRNA-1653, a combined human metapneumovirus and human parainfluenza virus type 3 vaccine, in healthy adults (18 to 49 years of age) and 2 dose levels in children (12 to 59 months of age) with serologic evidence of prio...
What is the current status of trial NCT04144348?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 51 participants. The study started on 2019-11-04. Estimated completion is 2022-12-20.
What conditions does trial NCT04144348 study?
This clinical trial studies the following conditions: Human Metapneumovirus and Human Parainfluenza Infection.
What interventions are being tested in trial NCT04144348?
The interventions under investigation include: Placebo (BIOLOGICAL), mRNA-1653 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04144348?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04144348 being conducted?
This trial has 19 study locations across Alabama, District of Columbia, Idaho, Kansas, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04144348's enrollment target sits among peer trials
51 969th of 2000 higher than 1,028 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI